Outcome of Misoprostol and Oxytocin in Induction of Labour

Overview

Journal SAGE Open Med

Publisher Sage Publications

Specialty General Medicine

Date 2017 May 26

PMID 28540049

Citations 8

Authors

Trishna Acharya

Ramesh Devkota

Bimbishar Bhattarai

Radha Acharya

Affiliations

Soon will be listed here.

Abstract

Background: Induction of labour is the process of initiating the labour by artificial means from 24 weeks of gestation. The main aim of this study is to find out the maternal and foetal outcomes after induction of labour with misoprostol and oxytocin beyond 37 weeks of gestation.

Methods: This was a hospital-based observational study carried out at Paropakar Maternity and Women's Hospital, Nepal. Misoprostol of 25 µg was inserted in posterior fornix of vagina or oxytocin infusion was started from 2.5 units on whom induction was decided. Maternal and foetal/neonatal outcomes were observed. Collected data were analysed using SPSS and MS Excel.

Results: General induction rate was found to be 7.2%. In this study, post-term pregnancy was found to be the most common reason for induction of labour. Analysis of onset of labour led to the finding that mean onset of labour was much rapid in oxytocin (6.6 h) than misoprostol (13.6 h). However, there is similarity in induction-delivery interval in both groups. Overall, the rate of normal delivery and caesarean section was found to be 64.9% and 33.2%, respectively. Similarly, normal delivery within 12 h was seen in 18.4% of the patients given with misoprostol and 43.5% in oxytocin group. Foetal distress was found as the most common reason for caesarean section. The overall occurrence of maternal complication was found to be similar in misoprostol and oxytocin groups, nausea/vomiting being the most common (36.7%) complication followed by fever (24.1%). Besides this, the most common neonatal complication found in overall cases was meconium stained liquor (49.2%).

Conclusion: It was found that misoprostol was used most frequently for induction of labour compared to oxytocin. The onset of labour was found to be rapid in oxytocin than misoprostol. However, the occurrence of side effects was found to be similar in both misoprostol and oxytocin groups.

Citing Articles

A comparative analysis of methods of preinduction cervical ripening and induction of labor in Poland and in Germany (Part II): maternal and neonatal outcomes.

Kleszcz A, Cwiek D, Sipak-Szmigiel O BMC Pregnancy Childbirth. 2025; 25(1):72.

PMID: 39871179 PMC: 11770951. DOI: 10.1186/s12884-024-07015-8.

Risk of Cesarean Delivery after Vaginal Inserts with Prostaglandin Analogs and Single-Balloon Catheter Used for Cervical Ripening and Induction of Labor.

Socha M, Flis W, Pietrus M, Wartega M Biomedicines. 2023; 11(8).

PMID: 37626622 PMC: 10452585. DOI: 10.3390/biomedicines11082125.

A Comparative Study of the Efficacy and Safety of Oral Misoprostol, Intravenous Oxytocin, and Intravaginal Dinoprostone for Labor Induction in Pakistani Women.

Wasim A, Khan M, Aneela F, Khan H, Solis M, Shabir I Cureus. 2023; 15(5):e39768.

PMID: 37398821 PMC: 10312116. DOI: 10.7759/cureus.39768.

The Efficacy of Misoprostol Vaginal Inserts for Induction of Labor in Women with Very Unfavorable Cervices.

Socha M, Flis W, Wartega M, Stankiewicz M, Kunicka A J Clin Med. 2023; 12(12).

PMID: 37373798 PMC: 10299393. DOI: 10.3390/jcm12124106.

Outcomes and Associated Factors of Induction of Labor in East Gojjam Zone, Northwest Ethiopia: A Multicenter Cross-Sectional Study.

Assemie M, Mihiret G, Mekonnen C, Petrucka P, Getaneh T, Ashebir W Obstet Gynecol Int. 2023; 2023:6910063.

PMID: 37351527 PMC: 10284654. DOI: 10.1155/2023/6910063.

References

Yawn B, Wollan P, McKeon K, Field C . Temporal changes in rates and reasons for medical induction of term labor, 1980-1996. Am J Obstet Gynecol. 2001; 184(4):611-9. DOI: 10.1067/mob.2001.110292. View

Divon M, Haglund B, Nisell H, Otterblad P, Westgren M . Fetal and neonatal mortality in the postterm pregnancy: the impact of gestational age and fetal growth restriction. Am J Obstet Gynecol. 1998; 178(4):726-31. DOI: 10.1016/s0002-9378(98)70482-x. View

Hofmeyr G, Gulmezoglu A . Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2003; (1):CD000941. DOI: 10.1002/14651858.CD000941. View

Prager M, Eneroth-Grimfors E, Edlund M, Marions L . A randomised controlled trial of intravaginal dinoprostone, intravaginal misoprostol and transcervical balloon catheter for labour induction. BJOG. 2008; 115(11):1443-50. DOI: 10.1111/j.1471-0528.2008.01843.x. View

Gulmezoglu A, Crowther C, Middleton P, Heatley E . Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev. 2012; (6):CD004945. PMC: 4065650. DOI: 10.1002/14651858.CD004945.pub3. View

Goldberg A, Wing D . Induction of labor: the misoprostol controversy. J Midwifery Womens Health. 2003; 48(4):244-8. DOI: 10.1016/s1526-9523(03)00087-4. View

Ingemarsson I, Kallen K . Stillbirths and rate of neonatal deaths in 76,761 postterm pregnancies in Sweden, 1982-1991: a register study. Acta Obstet Gynecol Scand. 1997; 76(7):658-62. DOI: 10.3109/00016349709024606. View

Dongol A, Shakya S, Chawla C . Safety and efficacy of misoprostol for induction of labour. J Nepal Health Res Counc. 2011; 8(1):27-30. View

Kramer R, Gilson G, Morrison D, Martin D, Gonzales J, Qualls C . A randomized trial of misoprostol and oxytocin for induction of labor: safety and efficacy. Obstet Gynecol. 1997; 89(3):387-91. DOI: 10.1016/s0029-7844(97)00363-3. View

10.

Daniel-Spiegel E, Weiner Z, Ben-Shlomo I, Shalev E . For how long should oxytocin be continued during induction of labour?. BJOG. 2004; 111(4):331-4. DOI: 10.1111/j.1471-0528.2004.00096.x. View

11.

Tang O, Gemzell-Danielsson K, Ho P . Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007; 99 Suppl 2:S160-7. DOI: 10.1016/j.ijgo.2007.09.004. View

12.

Gulmezoglu A, Crowther C, Middleton P . Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev. 2006; (4):CD004945. DOI: 10.1002/14651858.CD004945.pub2. View

13.

Shakya R, Shrestha J, Thapa P . Safety and efficacy of misoprostol and dinoprostone as cervical ripening agents. JNMA J Nepal Med Assoc. 2010; 49(177):33-7. View

14.

Heffner L, Elkin E, Fretts R . Impact of labor induction, gestational age, and maternal age on cesarean delivery rates. Obstet Gynecol. 2003; 102(2):287-93. DOI: 10.1016/s0029-7844(03)00531-3. View

15.

Heimstad R, Romundstad P, Eik-Nes S, Salvesen K . Outcomes of pregnancy beyond 37 weeks of gestation. Obstet Gynecol. 2006; 108(3 Pt 1):500-8. DOI: 10.1097/01.AOG.0000227783.65800.0f. View

16.

Kelly A, Tan B . Intravenous oxytocin alone for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2001; (3):CD003246. DOI: 10.1002/14651858.CD003246. View

17.

Hofmeyr G, Gulmezoglu A, Alfirevic Z . Misoprostol for induction of labour: a systematic review. Br J Obstet Gynaecol. 1999; 106(8):798-803. DOI: 10.1111/j.1471-0528.1999.tb08400.x. View

18.

Hofmeyr G, Gulmezoglu A . Vaginal misoprostol for cervical ripening and labour induction in late pregnancy. Cochrane Database Syst Rev. 2000; (2):CD000941. DOI: 10.1002/14651858.CD000941. View

19.

Kelly A, Malik S, Smith L, Kavanagh J, Thomas J . Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev. 2009; (4):CD003101. DOI: 10.1002/14651858.CD003101.pub2. View

20.

Sanchez-Ramos L, Kaunitz A, Wears R, Delke I, Gaudier F . Misoprostol for cervical ripening and labor induction: a meta-analysis. Obstet Gynecol. 1997; 89(4):633-42. DOI: 10.1016/S0029-7844(96)00374-2. View